A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing

Breast Cancer Clinical Trial

Official title:

A Phase 1 Open-Label Study of the Safety and Feasibility of ZYC300 Administration With Cyclophosphamide Pre-Dosing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT00381173
• Other study ID #: ZYC3-002
• Status: Completed
• Phase: Phase 1
• First received: September 26, 2006
• Last updated: May 13, 2013
• Start date: November 2006
• Est. completion date: October 2008

Study information

• Verified date: July 2011
• Source: Eisai Inc.
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug Administration
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the feasibility, safety, and tolerability of administering ZYC300 with Cyclophosphamide (Cytoxan).

Description:

This is an open-label study of ZYC300 in the treatment of advanced stage malignancy of the kidney in patients who have not had previous immune-based therapies or treatment of advanced stage malignancies (cancerous growths) of the ovary, breast, colon, or hormone-refractory prostate in patients who have failed at least one but no more than two prior regimens of chemotherapy. Patients who meet all entry criteria will be administered 600 mg/m^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).

ZYC300 is a plasmid DNA formulated within biodegradable microencapsulated particles. This is the first time that ZYC300 and Cyclophosphamide will be given together. Cyclophosphamide is a chemotherapy drug approved by the FDA that has been used for many years in many different kinds of cancer. In this trial the study drug will be used to boost the immune system. Sometimes the immune system cannot fight infected or abnormal cells because of other cells called T reg cells. The T reg cells limit the immune systems attack on infected or abnormal cells. In this study, the hope is that Cyclophosphamide will inhibit the T regs cells so that the ZYC300 can work better to attack the cancer cells.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 22
• Est. completion date: October 2008
• Est. primary completion date: October 2008
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

To be included in the study, patients must meet the following criteria:

1. Patients with:

Advanced stage malignancies who have failed treatment, including at least one, but no more than two, prior regimens of chemotherapy: Ovary, Breast, Colon, Hormone Refractory Prostate Cancer (HRPC), and renal.

2. Evidence of measurable disease by clinical or radiographic assessment or by tumor biomarker (ovarian and prostate cancer).

3. Age = 18 years old.

4. A baseline Eastern Cooperative Oncology Group Performance Status of 0 or 1.

5. A life expectancy > 6 months.

6. Adequate hematological function established within 14 days prior to receipt of the first dose of cyclophosphamide, defined as:

1. Absolute lymphocyte count = 1,000/mm^2

2. WBC = 3,000/mm^2

3. Platelet count = 75,000/mm^2

4. Hemoglobin = 9 g/dL

7. Adequate renal function established within 14 days prior to receipt of the first dose of cyclophosphamide, defined as serum creatinine = 1.5 X upper limit of normal.

8. Adequate hepatic function established within 14 days prior to receipt of the first dose of cyclophosphamide, defined as:

1. Total bilirubin = 1.5 X upper limit of normal, and

2. SGOT and SGPT = 2.5X upper limit of normal.

9. An MRI of the brain, if clinically indicated, which is negative for parenchymal central nervous system metastases within 28 days prior to receipt of the first dose of cyclophosphamide. If a patient cannot undergo an MRI because of a medical contraindication, a contrast CT of the brain will be acceptable.

10. A negative pregnancy test (blood or urine) within 14 days prior to first dose of cyclophosphamide (where applicable).

11. Agree to use appropriate contraception from study entry until the end-of-observation visit.

12. A signed informed consent form approved by the Institutional Review Board.

Exclusion Criteria:

Patients cannot participate in the study if any of the following apply:

1. Have a history of parenchymal brain metastases.

2. Have received any of the following within 28 days prior to receiving the first dose of cyclophosphamide:

1. Chemotherapy

2. Radiation therapy

3. Immunotherapy

4. Systemic immunosuppressive drugs

5. Glucocorticoids (inhalers for asthma are permitted)

6. Investigational agent or experimental therapy

3. Have received three or more biologic/targeted therapies, such as monoclonal antibodies and tyrosine kinase inhibitors.

4. Have initiated or reinitiated the use of hormonal agents within 28 days prior to receiving the first dose of cyclophosphamide. These drugs are allowed if treatment was initiated greater than 28 days prior to receipt of the first dose of cyclophosphamide.

5. Have a history of bone marrow or stem cell transplantation.

6. Have a history of treatment with fludarabine, 2-chlorodeoxyadenosine, 2-deoxycoformycin or similar compounds.

7. Have a history of treatment with chronic systemic immunosuppressive drugs.

8. Have an immunologic disorder such as immunodeficiency or other chronic auto-immune disease if deemed to be clinically significant.

9. Have an active systemic infection requiring treatment.

10. Are known to be positive for HIV antibody.

11. Pregnant or lactating.

12. Have a history of alcohol abuse, illicit drug use, or psychiatric disorder that would in the Investigator's opinion jeopardize protocol compliance or compromise the patient's ability to give informed consent.

13. Have had prior ex vivo or in vivo DNA therapy (administration of viral vectors or plasmid DNA formulations) or cancer vaccines.

14. Previous exposure to ZYC300 or amolimogene (HPV E6E7 plasmid; formerly known as ZYC101a).

Please note: There may be additional inclusion/exclusion criteria. The study center will determine if patients meet all of the criteria. If patients do not qualify for the trial, study personnel will explain the reasons. If patients do qualify, study personnel will explain the trial in detail using an IRB-approved informed consent, and answer any questions. Patients can then decide if they wish to participate.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Breast Cancer
• Carcinoma, Renal Cell
• Colon Cancer
• Kidney Neoplasms
• Ovarian Cancer
• Ovarian Neoplasms
• Prostate Cancer
• Prostatic Neoplasms
• Renal Cancer

Intervention

Drug:
• Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)
Patients who meet all entry criteria will be administered 600 mg/m^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).

Locations

Country	Name	City	State
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	M. D. Anderson Cancer Center	Houston	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Eisai Inc.

Country where clinical trial is conducted

United States, 

References & Publications (1)

Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, Nealon P, Matulonis U, Campos S, Gilligan TD, Richardson PG, Marshall B, Neuberg D, Nadler LM. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res. 2005 Jun 15;11(12):4430-6. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determine the feasibility, safety and tolerability of administering ZYC300 intramuscularly every other wk for 6 doses (400 micrograms DNA/total dose) to the study pop. pre-dosed with 600 mg/m^2 cyclophosphamide intravenously 3 days prior to study drug.		Within 14 days and 12 weeks post last dose of study drug (and 16 weeks post last dose for response confirmation, if applicable).	Yes
Secondary	Assess the effect of cyclophosphamide on T reg number and function. Assess the generation of CYP1B1-specific immun. as a result of vac. regimen. Assess the effect of vac. regimen on tumor response, if any, in pat. pop.		Within the first 14 days and at each subsequent visit.	No